{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T04:37:48Z","timestamp":1722573468791},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T00:00:00Z","timestamp":1365638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Micafungin (<jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content>) is an antifungal agent that is widely used for the treatment of invasive fungal infection. Although the pharmacokinetics of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> is considered to depend on the hepatic metabolism, the impact of hepatic function on the pharmacokinetics of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> has been inconsistent among previous studies. The object of this study was to evaluate the relationship between plasma <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> concentration and clinical and laboratory data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We examined the plasma concentration of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> in 10 patients who underwent allogeneic hematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>). <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> at 150\u00a0mg\/day was administered intravenously a median of 58.5\u00a0days after <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>. Trough and peak concentrations of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> (Cmin and Cmax) were measured at a median of 5.5\u00a0days after the first administration of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The presence of graft\u2010versus\u2010host disease involving the liver at blood sampling was associated with significantly higher Cmin and Cmax of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content>. Among the laboratory data, Cmin and Cmax were significantly higher in patients with severely impaired hepatic function defined as serum total bilirubin (TBi) level &gt;5\u00a0mg\/dL and\/or serum gamma\u2010glutamyltransferase (\u03b3\u2010<jats:styled-content style=\"fixed-case\">GTP<\/jats:styled-content>) level &gt;500\u00a0IU\/L, but the presence of mildly impaired hepatic function defined as serum TBi level &gt;2\u00a0mg\/dL and\/or serum \u03b3\u2010<jats:styled-content style=\"fixed-case\">GTP<\/jats:styled-content> level &gt;200\u00a0IU\/L did not affect Cmin and Cmax. Renal function did not show significant impact on Cmin and Cmax.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings suggest that the pharmacokinetics of <jats:styled-content style=\"fixed-case\">MCFG<\/jats:styled-content> is affected only by severely impaired liver function.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12070","type":"journal-article","created":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T03:14:18Z","timestamp":1365736458000},"page":"323-327","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"15","author":[{"given":"K.","family":"Oshima","sequence":"first","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"},{"name":"Department of Hematology and Oncology Graduate School of Medicine University of Tokyo Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"},{"name":"Department of Hematology and Oncology Graduate School of Medicine University of Tokyo Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kako","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"},{"name":"Department of Hematology and Oncology Graduate School of Medicine University of Tokyo Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kishino","sequence":"additional","affiliation":[{"name":"Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Graduate School of Medicine University of Tokyo Tokyo Japan"},{"name":"Department of Cell Therapy and Transplantation Medicine University of Tokyo Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585270-000000000-00000"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D301"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.033811"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410020406"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-007-0011-1"},{"issue":"1","key":"e_1_2_6_8_1","first-page":"104","article-title":"Phase I study of micafungin","volume":"50","author":"Azuma J","year":"2002","journal-title":"Jpn J Chemother"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2004.00272.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.21.324"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-006-0496-1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03191118"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.477"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.29.1886"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12070","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:07:35Z","timestamp":1700629655000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,11]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/tid.12070"],"URL":"https:\/\/doi.org\/10.1111\/tid.12070","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,11]]}}}